Effects of treatment in the levels of circulating cytokines and growth factors in cystic fibrosis and dialyzed patients by multi-analytical determination with a biochip array platform

Cytokine

Volumn 62, Issue 3, 2013, Pages 413-420

  Tirelli, Amedea Silvia ^a   Colombo, Carla ^a   Torresani, Erminio ^a   Fortunato, Francesca ^b   Biffi, Arianna ^a   Cariani, Lisa ^a   Daccò, Valeria ^a   Carbone, Annalucia ^a,b   Edefonti, Alberto ^a   Paglialonga, Fabio ^a   Conese, Massimo ^b  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^b UNIVERSITY OF FOGGIA   (Italy)

Author keywords

Biochip array technology; Chronic renal disease; Cystic fibrosis; Cytokines; Growth factors

Indexed keywords

ANTIBIOTIC AGENT; CYTOKINE; EPIDERMAL GROWTH FACTOR; GAMMA INTERFERON; GROWTH FACTOR; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; SIGNAL PEPTIDE;

ADOLESCENT; ADULT; ARTICLE; BIOCHIP; BIOCHIP ARRAY SYSTEM; CHILD; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CYSTIC FIBROSIS; DISEASE EXACERBATION; DISEASE MARKER; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HEMODIALYSIS PATIENT; HUMAN; LUNG DISEASE; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RESPIRATORY FUNCTION; SCHOOL CHILD; TREATMENT DURATION; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; VASCULAR DISEASE; BLOOD; CASE CONTROL STUDY; CHRONIC DISEASE; INFANT; METABOLISM; MICROARRAY ANALYSIS; PRESCHOOL CHILD; PROCEDURES; REGRESSION ANALYSIS; RENAL REPLACEMENT THERAPY; TREATMENT OUTCOME;

ADOLESCENT; ADULT; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; CHRONIC DISEASE; CYSTIC FIBROSIS; CYTOKINES; FEMALE; HUMANS; INFANT; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MICROARRAY ANALYSIS; REGRESSION ANALYSIS; RENAL DIALYSIS; TREATMENT OUTCOME;

EID: 84877796297     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2013.03.029     Document Type: Article

References (54)

1. Cohen T.S., Prince A. Cystic fibrosis: a mucosal immunodeficiency syndrome. Nat Med 2012, 18:509-519.
2. Rosenfeld M. An overview of endpoints for cystic fibrosis clinical trials: one size does not fit all. Proc Am Thorac Soc 2007, 4:299-301.
3. Sagel S.D., Chmiel J.F., Konstan M.W. Sputum biomarkers of inflammation in cystic fibrosis lung disease. Proc Am Thorac Soc 2007, 4:406-417.
4. Ionescu A.A., Nixon L.S., Shale D.J. Cellular proteolysis and systemic inflammation during exacerbation in cystic fibrosis. J Cyst Fibros 2004, 3:253-258.
5. Spittle M.A., Hoenich N.A., Handelman G.J., Adhikarla R., Homel P., Levin N.W. Oxidative stress and inflammation in hemodialysis patients. Am J Kidney Dis 2001, 38:1408-1413.
6. Pertosa G., Grandaliano G., Gesualdo L., Schena F.P. Clinical relevance of cytokine production in hemodialysis. Kidney Int Suppl 2000, 76. S104-11.
7. Horl W.H. Hemodialysis membranes: interleukins, biocompatibility, and middle molecules. J Am Soc Nephrol 2002, 13(Suppl 1):S62-S71.
8. Kim H.W., Woo Y.S., Yang H.N., Choi H.M., Jo S.K., Cho W.Y., et al. Primed monocytes: putative culprits of chronic low-grade inflammation and impaired innate immune responses in patients on hemodialysis. Clin Exp Nephrol 2011, 15:258-263.
9. Choi H.M., Woo Y.S., Kim M.G., Jo S.K., Cho W.Y., Kim H.K. Altered monocyte-derived dendritic cell function in patients on hemodialysis: a culprit for underlying impaired immune responses. Clin Exp Nephrol 2011, 15:546-553.
10. Carrero J.J., Stenvinkel P. Persistent inflammation as a catalyst for other risk factors in chronic kidney disease: a hypothesis proposal. Clin J Am Soc Nephrol 2009, 4(Suppl 1):S49-S55.
11. Miyamoto T., Carrero J.J., Stenvinkel P. Inflammation as a risk factor and target for therapy in chronic kidney disease. Curr Opin Nephrol Hypertens 2011, 20:662-668.
12. Stenbit A.E., Flume P.A. Pulmonary exacerbations in cystic fibrosis. Curr Opin Pulm Med 2011, 17:442-447.
13. Doring G., Conway S.P., Heijerman H.G., Hodson M.E., Hoiby N., Smyth A., et al. Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus. Eur Respir J 2000, 16:749-767.
14. American Thoracic Society Standardization of spirometry. Am J Respir Crit Care Med 1995, 152:1107-1136.
15. Fitzgerald S.P., Lamont J.V., McConnell R.I., Benchikh el O. Development of a high-throughput automated analyzer using biochip array technology. Clin Chem 2005, 51:1165-1176.
16. Molloy R.M., Mc Connell R.I., Lamont J.V., FitzGerald S.P. Automation of biochip array technology for quality results. Clin Chem Lab Med 2005, 43:1303-1313.
17. Sertic J., Slavicek J., Bozina N., Malenica B., Kes P., Reiner Z. Cytokines and growth factors in mostly atherosclerotic patients on hemodialysis determined by biochip array technology. Clin Chem Lab Med 2007, 45:1347-1352.
18. Colombo C., Faelli N., Tirelli A.S., Fortunato F., Biffi A., Claut L., et al. Analysis of inflammatory and immune response biomarkers in sputum and exhaled breath condensate by a multi-parametric biochip array in cystic fibrosis. Int J Immunopathol Pharmacol 2011, 24:423-432.
19. Tahergorabi Z., Khazaei M. Imbalance of angiogenesis in diabetic complications: the mechanisms. Int J Prev Med 2012, 3:827-838.
20. Farheen K., Agarwal S.K. Assessment of disease activity and treatment outcomes in rheumatoid arthritis. J Manage Care Pharm 2011, 17:S09-S13.
21. Celli B.R., Locantore N., Yates J., Tal-Singer R., Miller B.E., Bakke P., et al. Inflammatory biomarkers improve clinical prediction of mortality in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012.
22. Zethelius B., Berglund L., Sundstrom J., Ingelsson E., Basu S., Larsson A., et al. Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N Engl J Med 2008, 358:2107-2116.
23. Dorlochter L., Carlsson M., Olafsdottir E.J., Roksund O.D., Rosendahl K., Fluge G. Anti-neutrophil cytoplasmatic antibodies and lung disease in cystic fibrosis. J Cyst Fibros 2004, 3:179-183.
24. Meyer K.C., Lewandoski J.R., Zimmerman J.J., Nunley D., Calhoun W.J., Dopico G.A. Human neutrophil elastase and elastase/alpha 1-antiprotease complex in cystic fibrosis. Comparison with interstitial lung disease and evaluation of the effect of intravenously administered antibiotic therapy. Am Rev Respir Dis 1991, 144:580-585.
25. Downey D.G., Brockbank S., Martin S.L., Ennis M., Elborn J.S. The effect of treatment of cystic fibrosis pulmonary exacerbations on airways and systemic inflammation. Pediatr Pulmonol 2007, 42:729-735.
26. Downey D.G., Martin S.L., Dempster M., Moore J.E., Keogan M.T., Starcher B., et al. The relationship of clinical and inflammatory markers to outcome in stable patients with cystic fibrosis. Pediatr Pulmonol 2007, 42:216-220.
27. Levy H., Kalish L.A., Huntington I., Weller N., Gerard C., Silverman E.K., et al. Inflammatory markers of lung disease in adult patients with cystic fibrosis. Pediatr Pulmonol 2007, 42:256-262.
28. Jensen P.O., Moser C., Kharazmi A., Presler T., Koch C., Hoiby N. Increased serum concentration of G-CSF in cystic fibrosis patients with chronic Pseudomonas aeruginosa pneumonia. J Cyst Fibros 2006, 5:145-151.
29. Dean T.P., Dai Y., Shute J.K., Church M.K., Warner J.O. Interleukin-8 concentrations are elevated in bronchoalveolar lavage, sputum, and sera of children with cystic fibrosis. Pediatr Res 1993, 34:159-161.
30. Kronborg G., Hansen M.B., Svenson M., Fomsgaard A., Hoiby N., Bendtzen K. Cytokines in sputum and serum from patients with cystic fibrosis and chronic Pseudomonas aeruginosa infection as markers of destructive inflammation in the lungs. Pediatr Pulmonol 1993, 15:292-297.
31. Moser C., Jensen P.O., Pressler T., Frederiksen B., Lanng S., Kharazmi A., et al. Serum concentrations of GM-CSF and G-CSF correlate with the Th1/Th2 cytokine response in cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection. Apmis 2005, 113:400-409.
32. Louw J.J., Toelen J., Proesmans M., Vermeulen F., Billen J., de Boeck K. Serum procalcitonin is not an early marker of pulmonary exacerbation in children with cystic fibrosis. Eur J Pediatr 2012, 171:139-142.
33. Brown M.A., Morgan W.J., Finley P.R., Scuderi P. Circulating levels of tumor necrosis factor and interleukin-1 in cystic fibrosis. Pediatr Pulmonol 1991, 10:86-91.
34. Greally P., Hussein M.J., Cook A.J., Sampson A.P., Piper P.J., Price J.F. Sputum tumor necrosis factor-alpha and leukotriene concentrations in cystic fibrosis. Arch Dis Child 1993, 68:389-392.
35. Schmitt-Grohe S., Naujoks C., Bargon J., Wagner T.O., Schubert R., Hippe V., et al. Interleukin-8 in whole blood and clinical status in cystic fibrosis. Cytokine 2005, 29:18-23.
36. Norman D., Elborn J.S., Cordon S.M., Rayner R.J., Wiseman M.S., Hiller E.J., et al. Plasma tumour necrosis factor alpha in cystic fibrosis. Thorax 1991, 46:91-95.
37. Wilmott R.W., Frenzke M., Kociela V., Peng L. Plasma interleukin-1 alpha and beta, tumor necrosis factor-alpha, and lipopolysaccharide concentrations during pulmonary exacerbations of cystic fibrosis. Pediatr Pulmonol 1994, 18:21-27.
38. McColley S.A., Stellmach V., Boas S.R., Jain M., Crawford S.E. Serum vascular endothelial growth factor is elevated in cystic fibrosis and decreases with treatment of acute pulmonary exacerbation. Am J Respir Crit Care Med 2000, 161:1877-1880.
39. Park Y., Park Y., Han K.H., Kim H.S. Serum cytokine levels in patients with chronic hepatitis B according to lamivudine therapy. J Clin Lab Anal 2011, 25:414-421.
40. Dogliotti G., Galliera E., Licastro F., Corsi M.M. Age-related changes in plasma levels of BDNF in Down syndrome patients. Immun Ageing 2010, 7:2.
41. Berrahmoune H., Lamont J.V., Herbeth B., FitzGerald P.S., Visvikis-Siest S. Biological determinants of and reference values for plasma interleukin-8, monocyte chemoattractant protein-1, epidermal growth factor, and vascular endothelial growth factor: Results from the STANISLAS cohort. Clin Chem 2006, 52:504-510.
42. Moser C., Kjaergaard S., Pressler T., Kharazmi A., Koch C., Hoiby N. The immune response to chronic Pseudomonas aeruginosa lung infection in cystic fibrosis patients is predominantly of the Th2 type. Apmis 2000, 108:329-335.
43. Hartl D., Griese M., Kappler M., Zissel G., Reinhardt D., Rebhan C., et al. Pulmonary T(H)2 response in Pseudomonas aeruginosa-infected patients with cystic fibrosis. J Allergy Clin Immunol 2006, 117:204-211.
44. Colombo C., Costantini D., Rocchi A., Cariani L., Garlaschi M.L., Tirelli S., et al. Cytokine levels in sputum of cystic fibrosis patients before and after antibiotic therapy. Pediatr Pulmunol 2005, 40:15-21.
45. Fioretto J.R., Martin J.G., Kurokawa C.S., Carpi M.F., Bonatto R.C., Ricchetti S.M., et al. Interleukin-6 and procalcitonin in children with sepsis and septic shock. Cytokine 2008, 43:160-164.
46. Regamey N., Tsartsali L., Hilliard T.N., Fuchs O., Tan H.L., Zhu J., et al. Distinct patterns of inflammation in the airway lumen and bronchial mucosa of children with cystic fibrosis. Thorax 2012, 67:164-170.
47. Harris W.T., Muhlebach M.S., Oster R.A., Knowles M.R., Clancy J.P., Noah T.L. Plasma TGF-beta(1) in pediatric cystic fibrosis: potential biomarker of lung disease and response to therapy. Pediatr Pulmonol 2011, 46:688-695.
48. Carrero J.J., Stenvinkel P. Inflammation in end-stage renal disease-what have we learned in 10 years?. Semin Dial 2010, 23:498-509.
49. Meuwese C.L., Stenvinkel P., Dekker F.W., Carrero J.J. Monitoring of inflammation in patients on dialysis: forewarned is forearmed. Nat Rev Nephrol 2011, 7:166-176.
50. Girndt M., Heisel O., Kohler H. Influence of dialysis with polyamide vs haemophan haemodialysers on monokines and complement activation during a 4-month long-term study. Nephrol Dial Transplant 1999, 14:676-682.
51. Memoli B., Marzano L., Bisesti V., Andreucci M., Guida B. Hemodialysis-related lymphomononuclear release of interleukin-12 in patients with end-stage renal disease. J Am Soc Nephrol 1999, 10:2171-2176.
52. Friedrich B., Alexander D., Janessa A., Haring H.U., Lang F., Risler T. Acute effects of hemodialysis on cytokine transcription profiles: evidence for C-reactive protein-dependency of mediator induction. Kidney Int 2006, 70:2124-2130.
53. Papayianni A., Alexopoulos E., Giamalis P., Gionanlis L., Belechri A.M., Koukoudis P., et al. Circulating levels of ICAM-1, VCAM-1, and MCP-1 are increased in haemodialysis patients: association with inflammation, dyslipidaemia, and vascular events. Nephrol Dial Transplant 2002, 17:435-441.
54. Girndt M., Sester U., Kaul H., Kohler H. Production of proinflammatory and regulatory monokines in hemodialysis patients shown at a single-cell level. J Am Soc Nephrol 1998, 9:1689-1696.